Redx Pharma announces final audited results for 15-month period ended Dec. 31, 2025
Redx Pharma reported audited results for the 15-month period ended Dec. 31, 2025, after changing its financial year-end. The company also said it expects its Skye Bioscience transaction and financing, with aggregate gross proceeds of up to $125 million, to close in Q4 2026.